Clinical trials: Lung Cancer, Adenocarcinoma
Lung Cancer, Lung Adenocarcinoma
Identify Prognostic Biomarkers of Lung Cancer
Multi-omics and Clinical Data Analysis is potential to predict the prognosis of lung cancer patients.
- Conditions
- Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT05010330
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Bladder Cancer, Breast Cancer
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
RATIONALE: OGX-011 may kill tumor cells by blocking some of the proteins that may cause tumor cells to grow. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Conditions
- Bladder Cancer, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00471432
- Testing
- custirsen sodium, docetaxel, pharmacological study
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer, Colorectal Cancer
Family Quality of Life Among Families With a Member Who is a Cancer Patient
RATIONALE: Developing a questionnaire that can be used to assess the quality of life among people who have a family member with cancer may help the study of cancer in the future.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00544336
- Testing
- questionnaire administration, survey administration, quality-of-life assessment
- Where
- 3 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lung Cancer
Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00560495
- Testing
- ammonium tetrathiomolybdate, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Lung Cancer
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients with relapsed or…
- Trial name
- NCT00003666
- Testing
- 6-hydroxymethylacylfulvene
- Where
- 48 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Adenocarcinoma
Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)
This is a phase II study aimed to assess the efficacy and safety of furmonertinib, a third generation EGFR TKI, as perioperation therapy in stage IIIA-IIIB (N1-N2) resectable NSCLC patients.
- Trial name
- NCT04965831
- Testing
- Furmonertinib
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
This phase I/II trial studies the side effects and best dose of aerosolized aldesleukin and to see how well it works in treating patients with cancer that has spread from the original tumor to the lungs.
- Conditions
- Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma, Metastatic Renal Cell Cancer
- Trial name
- NCT01590069
- Testing
- Aerosolized Aldesleukin, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction.
- Conditions
- Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT04267575
- Testing
- Canady Helios Cold Plasma Scalpel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jerome Canady, M.D.
Lung Tumor, Bone Tumor
Preliminary Study of Microwave Tumoral Ablation Performances for the Treatment of Pulmonary, Renal and Bone Neoplasia.
The aims of this work were to assess the feasibility, efficacy, short-term outcome and safety of microwave ablation in the treatment of malignant bone, lung and renal tumors.
- Conditions
- Lung Tumor, Bone Tumor, Renal Tumor
- Trial name
- TherMO (NCT02862288)
- Testing
- Microwave ablation with Acculis Accu2i pMTA Applicator
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
This phase II clinical trial studies how well thermal ablation and spine stereotactic radiosurgery work in treating patients with cancer that has spread to the spine (spine metastases) and is at risk for compressing the spinal…
- Conditions
- Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine
- Trial name
- NCT02713269
- Testing
- Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
- Conditions
- Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05795595
- Testing
- CTX131
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- CRISPR Therapeutics AG
Non Small Cell Lung Cancer, Metastatic Melanoma
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
This is a phase I/II study that will evaluate the safety and toxicity of this combinatorial approach. Eligible patients >18 years of age with histologically proven metastatic NSCLC, melanoma, RCC, or HNSCC who have failed PD-1 /…
- Conditions
- Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03474497
- Testing
- IL-2, Pembrolizumab, Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Megan Daly, MD
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor, as…
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms
- Trial name
- NCT04862780
- Testing
- BLU-945, osimertinib
- Where
- 26 sites in United States, Canada and 8 more
- Volunteers
- 177 people
- Sponsor
- Blueprint Medicines Corporation
Cancer
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
Heat shock protein 90 (Hsp90) is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90.
- Trial name
- NCT01851096
- Testing
- SNX-5422
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Esanex Inc.
Gastric Cancer, Hepatic Carcinoma
Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
This study retrospectively analyzed patients who underwent tracheal intubation under general anesthesia at the First Affiliated Hospital of Zhejiang University School of Medicine between October 1, 2015, and September 30, 2025…
- Conditions
- Gastric Cancer, Hepatic Carcinoma, Pulmonary Carcinoma, Pancreatic Carcinoma
- Trial name
- NCT07359586
- Where
- 2 sites in China
- Volunteers
- 1,200 people
- Sponsor
- Zhejiang University
Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic…
- Conditions
- Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell
- Trial name
- NCT02443324
- Testing
- Ramucirumab, Pembrolizumab
- Where
- 22 sites in United States, France and 4 more
- Volunteers
- 175 people
- Sponsor
- Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer
Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed…
- Trial name
- DARANIVOVAX (NCT06015724)
- Testing
- Daratumumab, KRAS vaccine, Nivolumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Georgetown University
Advanced Solid Tumor, Metastatic Solid Tumors
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
- Trial name
- SHIELD-1 (NCT03993873)
- Testing
- elzovantinib (TPX-0022)
- Where
- 24 sites in United States, France and 3 more
- Volunteers
- 95 people
- Sponsor
- Turning Point Therapeutics, Inc.
Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
This phase II trial studies how well image guided hypofractionated radiation therapy works with nelfinavir mesylate, pembrolizumab, nivolumab, and atezolizumab in treating patients with melanoma, lung cancer, or kidney cancer…
- Conditions
- Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT03050060
- Testing
- Atezolizumab, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Washington
Lung Cancer
Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00398385
- Testing
- cisplatin, gemcitabine hydrochloride, adjuvant therapy
- Where
- South Korea
- Volunteers
- 170 people
- Sponsor
- National Cancer Center, Korea
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.